Sanofi-Aventis To Pay $4 Billion For Merial

$4B price tag for Merial paid by Sanofi-Aventis.

Merck & Co. has agreed to sell its 50 percent interest in Merial to Sanofi-Aventis SA, which owns the other half of the animal health company, for $4 billion in cash.

The sale is subject to clearance by European antitrust authorities.

The companies made the announcement in a joint statement dated July 30.

Merck anticipates completing the transaction before Merck's planned $41.1 billion merger with Schering-Plough Corp. The merger is expected to close in the fourth quarter.

In addition, Merck, Sanofi-Aventis and Schering-Plough have signed a call option agreement. This means that after the close of the Merck/Schering-Plough merger, Sanofi-Aventis will have the option to combine the Intervet/Schering-Plough Animal Health business with Merial to form an animal health joint venture that would be owned equally by itself and the new Merck.

Any formation of a new animal health joint venture with Sanofi-Aventis is subject to antitrust reviews in the U.S. and Europe.

Sanofi-Aventis is based in Paris, Merck is in Whitehouse Station, N.J., and Schering-Plough is in Kenilworth, N.J.

<HOME>

 

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.